Introduction
The stroke market is ripe for the taking. Existing treatments are limited, and the unmet medical need is great. In contrast to breakthroughs in many diseases over the past two decades, stroke treatment, especially from drugs, has had minimal improvement for the past 23 years. Large biopharmaceutical companies such as Biogen (BIIB) are building whole drug development portfolios for stroke, while other companies like SanBio (SNBIF) are researching more creative ways to treat stroke, such as via regeneration months after the stroke. Readers who read my recent Athersys (